STOCK TITAN

Incyte (INCY) EVP reports tax withholding and sale of 10,856 shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Incyte Corp executive Issa Mohamed Khairie reported both tax withholding and a share sale of company stock. On January 6, 2026, 8,264 shares of common stock were automatically withheld by Incyte at $106.66 per share to cover tax obligations tied to previously granted restricted stock units. On January 7, 2026, Khairie sold 10,856 shares of Incyte common stock at an average price of $109.07 per share in an open-market transaction. Following these transactions, he beneficially owned 66,132 shares of common stock, which the filing states includes shares issuable under unvested restricted stock units.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Issa Mohamed Khairie

(Last) (First) (Middle)
1801 AUGUSTINE CUT-OFF

(Street)
WILMINGTON DE 19803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Head of US Oncology
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/06/2026 F 8,264(1) D $106.66 76,988 D
Common Stock 01/07/2026 S 10,856 D $109.07 66,132(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.
2. This includes an aggregate of 66,132 shares of common stock issuable pursuant to previously reported RSUs that have not vested.
Remarks:
/s/ Elizabeth Feeney, Attorney-In-Fact 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Incyte (INCY) report for Issa Mohamed Khairie?

The filing shows that EVP, Head of US Oncology Issa Mohamed Khairie had 8,264 shares withheld for taxes on January 6, 2026 and sold 10,856 shares of Incyte common stock on January 7, 2026.

How many Incyte (INCY) shares did the executive sell and at what price?

On January 7, 2026, Issa Mohamed Khairie sold 10,856 shares of Incyte common stock in a transaction coded "S" at an average price of $109.07 per share.

What does the tax withholding transaction in the Incyte Form 4 represent?

The 8,264-share transaction on January 6, 2026, coded "F", represents shares automatically withheld by Incyte to satisfy tax withholding obligations upon settlement of previously reported restricted stock units.

How many Incyte shares does the reporting person beneficially own after these transactions?

After the reported transactions, Issa Mohamed Khairie beneficially owned 66,132 shares of Incyte common stock, which the filing notes includes shares issuable from previously reported unvested restricted stock units.

What is Issa Mohamed Khairie's role at Incyte (INCY)?

Issa Mohamed Khairie is an officer of Incyte, serving as EVP, Head of US Oncology, as disclosed in the Form 4.

Are the Incyte Form 4 transactions reported as directly owned by the executive?

Yes. The Form 4 lists both transactions in common stock as directly owned (D) by Issa Mohamed Khairie, with no indication of indirect ownership through another entity.

Incyte Corp

NASDAQ:INCY

INCY Rankings

INCY Latest News

INCY Latest SEC Filings

INCY Stock Data

20.66B
192.26M
2.03%
103.47%
3.85%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON